A
lexandria to Lead Mission-Critical Panel on Immunology and Inflammation at 2024 Galien Forum USA

    Alexandria Real Estate Equities, Inc., a leading owner, operator, and developer of collaborative life science campuses, will lead a mission-critical panel on immunology and inflammation as a cornerstone of treating human disease. The panel, titled "Immunology & Inflammation – A Cornerstone of Treating Human Disease," will take place at the 2024 Galien Forum USA at the Alexandria Center for Life Science in New York City.

    The panel, co-moderated by Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc., and Lynne Zydowsky, PhD, chief of science of Alexandria, will feature pioneers in immunology discussing the latest advances, current challenges, and future opportunities for harnessing the immune system to combat chronic and inflammatory disorders.

    Immunology has emerged as a fundamental area of research in addressing human diseases. Recent breakthroughs have led to revolutionary therapies and opened new frontiers in medical science. The global immunology market is expected to more than double from nearly $103 billion in 2024 to $257 billion by 2032, making it the second-largest area of biopharmaceutical spend behind oncology.

    Alexandria's panel will explore how immunological and anti-inflammatory approaches are reshaping our understanding of disease mechanisms and opening new opportunities for treatment. The latest developments, including engineered cell therapies and novel immunomodulatory drugs, hold promise to transform the treatment landscape for millions of patients worldwide.

    As a pioneer in the life science real estate niche, Alexandria has a remarkable track record of partnering with trailblazing life science companies to enable the development of life-changing and lifesaving treatments and cures. Since 2013, Alexandria tenants have developed or commercialized half the novel FDA-approved therapies, and so far in 2024, they have been responsible for over 80% of the FDA approvals for innovative medicines.

    The company's mission-driven approach has enabled it to foster the development of new therapies and cures for the 10,000 diseases known to humankind. With $4.5 trillion in U.S. healthcare spending in 2022, the opportunity to reduce the economic burden on the country and better manage disease for patients through the development of new innovative medicines remains immense.

    Alexandria's panel will be a pivotal discussion on the latest advances and future opportunities in immunology and inflammation, highlighting the company's commitment to driving innovation and improving human health and well-being.